search
Back to results

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

Primary Purpose

Type 2 Diabetes Mellitus

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
PF-05175157
Placebo
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with Type 2 Diabetes Mellitus and treated with metformin at a dose greater than or equal to 1000 mg for at least 3 months
  • Hemoglobin A1c of 7-10% at screening.
  • Body Mass Index of at least 25 kg/m2.

Exclusion Criteria:

  • Compliant with study drug administration during the run-in period and throughout the trial.
  • Patients with fasting triglycerides greater than 500 mg/dL at screening.
  • History of certain diabetic complications or cardiac problems.

Sites / Locations

  • Pfizer Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

PF-05175157

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo

Secondary Outcome Measures

Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo
Change from baseline in fasting plasma glucose
Change from baseline in Glycosylated Hemoglobin (HbA1c)
Change from baseline in fasting total cholesterol
Change from baseline in glucose AUC(0-5) during mixed meal tolerance test (MMTT)
Change from baseline in insulin AUC(0-5) during mixed meal tolerance test (MMTT)
Change from baseline in ratio of AUC (0-5) C-peptide to AUC(0-5) glucose during the MMTT
Change from baseline in ratio of AUC(0-5) insulin to AUC(0-5) glucose during the MMTT
Change from baseline in homeostatic model assessment for insulin resistance (HOMA IR)
Change from baseline in homeostatic model assessment for β-cell function (HOMA B)
Plasma concentrations for PF-05175157
Percent change from baseline in body weight
Change from baseline in low density lipoprotein cholesterol (LDL-C)
Change from baseline in high density lipoprotein cholesterol (HDL-C)
Change from baseline in triglycerides
Change from baseline in non-HDL cholesterol
Change from baseline in very low density lipoprotein (VLDL)

Full Information

First Posted
January 30, 2014
Last Updated
March 29, 2016
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT02053103
Brief Title
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin
Official Title
A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 In Adult Subjects With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Terminated
Why Stopped
On 25April2014, study was terminated before any dosing due to an AE of safety concern that occurred in protocol B1731003 with the same drug.
Study Start Date
March 2014 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks in adult subjects with Type 2 Diabetes Mellitus (T2DM) on metformin background therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PF-05175157
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
PF-05175157
Intervention Description
Tablet, 200 mg, twice daily, 6 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Tablet, 0 mg, twice daily, 6 weeks
Primary Outcome Measure Information:
Title
Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo
Time Frame
Baseline, Day 42
Secondary Outcome Measure Information:
Title
Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo
Time Frame
Weeks 0 and 4
Title
Change from baseline in fasting plasma glucose
Time Frame
Weeks 0, 2, 4 and 6
Title
Change from baseline in Glycosylated Hemoglobin (HbA1c)
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in fasting total cholesterol
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in glucose AUC(0-5) during mixed meal tolerance test (MMTT)
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in insulin AUC(0-5) during mixed meal tolerance test (MMTT)
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in ratio of AUC (0-5) C-peptide to AUC(0-5) glucose during the MMTT
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in ratio of AUC(0-5) insulin to AUC(0-5) glucose during the MMTT
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in homeostatic model assessment for insulin resistance (HOMA IR)
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in homeostatic model assessment for β-cell function (HOMA B)
Time Frame
Weeks 0, 4 and 6
Title
Plasma concentrations for PF-05175157
Time Frame
Weeks 2, 4 and 6
Title
Percent change from baseline in body weight
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in low density lipoprotein cholesterol (LDL-C)
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in high density lipoprotein cholesterol (HDL-C)
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in triglycerides
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in non-HDL cholesterol
Time Frame
Weeks 0, 4 and 6
Title
Change from baseline in very low density lipoprotein (VLDL)
Time Frame
Weeks 0, 4 and 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with Type 2 Diabetes Mellitus and treated with metformin at a dose greater than or equal to 1000 mg for at least 3 months Hemoglobin A1c of 7-10% at screening. Body Mass Index of at least 25 kg/m2. Exclusion Criteria: Compliant with study drug administration during the run-in period and throughout the trial. Patients with fasting triglycerides greater than 500 mg/dL at screening. History of certain diabetic complications or cardiac problems.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Pfizer Investigational Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32809
Country
United States

12. IPD Sharing Statement

Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731002&StudyName=A%206-Week%20Study%20To%20Determine%20The%20Safety%20And%20Effect%20Of%20An%20Investigational%20Drug%20On%20Adults%20With%20Type%202%20Diabetes%20Mellitus%20Taking%20Metformi
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

We'll reach out to this number within 24 hrs